AstraZeneca PLC Begins Global Phase 3 Study of Breast Cancer Faslodex

Published: Oct 29, 2012

AstraZeneca (AZN) today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy. The Phase III study is designed to evaluate the efficacy and tolerability of fulvestrant 500 mg compared to anastrozole 1 mg in this patient population.

Back to news